Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial

Part of paid clinical trials in Los Angeles, California.

Sponsor
Jonsson Comprehensive Cancer Center
Study ID
NCT06432036
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Stage I Renal Cell Cancer
  • Stage II Renal Cell Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Angiogram — PROCEDURE
    Undergo angiogram
  • Biospecimen Collection — PROCEDURE
    Undergo blood sample collection
  • Computed Tomography — PROCEDURE
    Undergo CT scan
  • Radioembolization — RADIATION
    Undergo radioembolization
  • Single Photon Emission Computed Tomography — PROCEDURE
    Undergo SPECT
  • Survey Administration — OTHER
    Ancillary study
  • Yttrium Y 90 Glass Microspheres — RADIATION
    Given intra-arterially

Study Details

This phase I/II trial tests the safety, side effects and effectiveness of radioembolization with yttrium-90 (Y-90) in patients with early stage renal cell carcinoma. Y-90 is a radioactive chemical that is incorporated into millions of very tiny glass spheres. These spheres are injected into the artery that feeds the cancer. This process is called radioembolization. Y-90 radioembolization may be a safe and effective treatment for patients with early stage renal cell carcinoma.

Key Dates

Start date
Dec 26, 2024
Status verified
Feb 2026
Primary completion
Mar 24, 2029
Completion
Mar 31, 2030

Study Design

Enrollment
25 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (radioembolization, TheraSphere)
    Patients undergo radioembolization with TheraSphere given intra-arterially. Patients undergo angiogram during screening, SPECT scan on study and CT scan and blood sample collection throughout the study.

Primary Outcome Measure

Number of treatment related adverse events [ Time Frame: Up to 2 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UCLA / Jonsson Comprehensive Cancer CenterLos AngelesCalifornia90095
Aniket U. Joglekar
[email protected]
(310) 948-8026
Saima Chaabane
[email protected]
(310)794-8995
Siddharth A. Padia, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Angeles, CA

By research site
UCLA / Jonsson Comprehensive Cancer Center· Los Angeles, CA

Related Studies